+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Alopecia Drugs Market (2021-2026) by Alopecia Types, Drugs, Route of Administration, Gender, Sales Channel, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • ID: 5410421
  • Report
  • June 2021
  • Region: Global
  • 192 Pages
  • Infogence Global Research
The Global Alopecia Drugs Market is estimated to be USD 869.4 Mn in 2021 and is expected to reach USD 1462.35 Mn by 2026, growing at a CAGR of 10.96%.



Market Dynamics

The major factor contributing to the growth of the alopecia drug market is the rising awareness about alopecia owing to rising stress levels, sedentary lifestyle, hormonal changes, and hereditary conditions. Furthermore, the rise in pollution and the growing geriatric population have increased the cases of hair loss. In addition, the increasing prevalence of cancer, hypertension, depression, etc., leading to hair loss, has raised the demand for the alopecia drugs market. However, as alopecia is not a life-threatening condition and lacks proper approved treatment, various patients do not opt for the treatment, which has hindered the market.
The increasing research and development for novel drug treatment of alopecia are anticipated to drive the market during the forecast period.

Market Segmentation

The Global Alopecia Drugs Market is segmented further based on Alopecia Types, Drugs, Route of Administration, Gender, Sales Channel, and Geography.

By Alopecia Types, the market is classified as Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Cicatricial Alopecia, Traction Alopecia, Tinea Capitis, Androgenetic Alopecia, Anagen Effluvium, and Others. Amongst all, the Alopecia Areata segment is estimated to hold the highest market share during the forecast period.

By Drugs, the market is classified as Vasodilators (Minoxidil), 5-Alpha Reductase Inhibitors (Finasteride), Corticosteroids, and Others. Amongst all, the Vasodilators (Minoxidil) segment is estimated to hold the highest market share during the forecast period.

By Route of Administration, the market is classified into Injectable, Oral, and Topical. Amongst all, Injectable segment is estimated to hold the highest market share during the forecast period.

By Gender, the market is classified as Men And Women. Amongst the two, Women segment is estimated to hold the highest market share during the forecast period.

By Sales Channel, the market is classified as Prescriptions and OTC. Amongst the two, Prescriptions segment is estimated to hold the highest market share during the forecast period.

By Geography, North America is projected to lead the market.

Recent Developments

1. Concert Pharmaceuticals received the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the Company’s oral Janus kinase inhibitor, CTP-543, for the treatment of adult patients with moderate-to-severe alopecia areata. - 8th July 2020
2. Baricitinib is First JAK-Inhibitor received FDA approval in Phase 3 Alopecia Areata (AA) Trial - 3 rd March 2021

Company Profiles

Some of the companies covered in this report are Cipla, Sun Pharmaceutical, Ranbaxy, Aurobindo, Accord Healthcare, Taisho Pharmaceutical, etc.

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Alopecia Drugs Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the analyst’s Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Alopecia Drugs Market

What is the estimated value of the Global Alopecia Drugs Market?

The Global Alopecia Drugs Market was estimated to be valued at $869.4 Million in 2021.

What is the growth rate of the Global Alopecia Drugs Market?

The growth rate of the Global Alopecia Drugs Market is 11.0%, with an estimated value of $1462.4 Million by 2026.

What is the forecasted size of the Global Alopecia Drugs Market?

The Global Alopecia Drugs Market is estimated to be worth $1462.4 Million by 2026.

Who are the key companies in the Global Alopecia Drugs Market?

Key companies in the Global Alopecia Drugs Market include Cipla, Sun Pharmaceutical, Micro Labs, Torrent Pharma, Indiabulls Pharmaceutical, Johnson & Johnson, Merck, Kirkland Signature and GlaxoSmithKline.

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size and Segmentation
3.3 Market Outlook
4 Market Influencers
4.1 Drivers
4.1.1 Growing Awareness Regarding Alopecia Drugs
4.1.2 Increasing Prevalence of Diseases and Drugs Inducing Alopecia
4.1.3 Rising Geriatric Population and Sedentary Lifestyle
4.2 Restraints
4.2.1 High Cost Of Medicine
4.2.2 Stringent Government Regulations
4.3 Opportunities
4.3.1 Ongoing Research and Development in Alopecia Drugs
4.3.2 Increasing Healthcare Expenditure Emerging Countries
4.4 Challenges
4.4.1 Adoption of Substitutes
4.4.2 Discontinuation and Low Adoption of Treatment
4.5 Trends
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter’s Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Alopecia Drugs Market, By Alopecia Types
6.1 Introduction
6.2 Alopecia Areata
6.3 Alopecia Totalis
6.4 Alopecia Universalis
6.5 Cicatricial Alopecia
6.6 Traction Alopecia
6.7 Tinea Capitis
6.8 Androgenetic Alopecia
6.9 Anagen Effluvium
6.10 Others
7 Global Alopecia Drugs Market, By Drugs
7.1 Introduction
7.2 Vasodilators (Minoxidil)
7.3 5-Alpha Reductase Inhibitors (Finasteride)
7.4 Corticosteroids
7.5 Others
8 Global Alopecia Drugs Market, By Route of Administration
8.1 Introduction
8.2 Injectable
8.3 Oral
8.4 Topical
9 Global Alopecia Drugs Market, By Gender
9.1 Introduction
9.2 Men
9.3 Women
10 Global Alopecia Drugs Market, By Sales Channel
10.1 Introduction
10.2 Prescriptions
10.3 OTC
11 Global Alopecia Drugs Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 South America
11.3.1 Brazil
11.3.2 Argentina
11.3.3 Chile
11.3.4 Colombia
11.4 Europe
11.4.1 UK
11.4.2 France
11.4.3 Germany
11.4.4 Italy
11.4.5 Spain
11.4.6 Netherlands
11.4.7 Sweden
11.4.8 Russia
11.4.9 Rest of Europe
11.5 Asia-Pacific
11.5.1 China
11.5.2 Japan
11.5.3 India
11.5.4 Indonesia
11.5.5 Malaysia
11.5.6 South Korea
11.5.7 Australia
11.5.8 Sri Lanka
11.5.9 Thailand
11.5.10 Rest of APAC
11.6 Middle-East and Africa
11.6.1 Qatar
11.6.2 Saudi Arabia
11.6.3 South Africa
11.6.4 United Arab Emirates
12 Competitive Landscape
12.1 Competitive Quadrant
12.2 Market Share Analysis
12.3 Strategic Initiatives
12.3.1 M&A and Investments
12.3.2 Partnerships and Collaborations
12.3.3 Product Developments and Improvements
13 Company Profiles
13.1 Cipla
13.2 Sun Pharmaceutical
13.3 Micro Labs
13.4 Torrent Pharma
13.5 Indiabulls Pharmaceutical
13.6 Johnson & Johnson
13.7 Merck
13.8 Kirkland Signature
13.9 Histogen
13.10 GlaxoSmithKline
13.11 L`Oreal
13.12 Concert Pharmaceuticals
13.13 Aurobindo
13.14 Accord Healthcare
13.15 Ranbaxy
13.16 Taisho Pharmaceutical
13.17 Theradome
13.18 Intas Pharmaceuticals
13.19 Abbott
13.20 Avacor
13.21 Glenmark
14 Appendix
14.1 Questionnaire

Companies Mentioned

  • Cipla
  • Sun Pharmaceutical
  • Micro Labs
  • Torrent Pharma
  • Indiabulls Pharmaceutical
  • Johnson & Johnson
  • Merck
  • Kirkland Signature
  • Histogen
  • GlaxoSmithKline
  • L`Oreal
  • Concert Pharmaceuticals
  • Aurobindo
  • Accord Healthcare
  • Ranbaxy
  • Taisho Pharmaceutical
  • Theradome
  • Intas Pharmaceuticals
  • Abbott
  • Avacor
  • Glenmark